英国国民健康服务局将阿比拉的治疗范围扩大到高危前列腺癌患者的8000人, 导致复发率减半, 死亡率降低40%. NHS England expands abiraterone access to 8,000 high-risk prostate cancer patients, halving recurrence and cutting deaths by 40%.

英格兰国家卫生服务局现在将向每年约8 000名患有高风险、非转移性疾病的男子提供前列腺癌症药物乙酮,将扩大治疗范围,超越先进的病例。 NHS England will now provide the prostate cancer drug abiraterone to about 8,000 men annually with high-risk, non-metastatic disease, expanding access beyond advanced cases. 根据有力的试验证据,在标准护理下使用的治疗癌症复发风险和将死亡风险降低40%,可能每年将前列腺癌死亡人数从1 900人减少到1 000人以下。 Based on strong trial evidence, the treatment—used with standard care—halves cancer recurrence risk and reduces death risk by 40%, potentially cutting annual prostate cancer deaths from 1,900 to under 1,000. 这一行动是在苏格兰和威尔士成功使用之后采取的,是在英格兰国家保健服务机构利用其他治疗的节余获得资金之后采取的。 The move follows successful use in Scotland and Wales, and comes after NHS England secured funding using savings from other treatments. 卫生官员和慈善机构称它为早期护理的一大进步,有可能在五年内拯救3 000多人的生命。 Health officials and charities call it a major advancement in early-stage care, with potential to save over 3,000 lives in five years.